Genocury develops iPS-derived CAR-NKT cell therapy products using gene editing and directed differentiation technologies to provide affordable treatment options for cancer patients. The company focuses on creating off-the-shelf immune cell therapies that enhance patient access to effective cancer treatments while maintaining cost-effectiveness.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatment options are often expensive and inaccessible, limiting patient access to effective therapies. Traditional CAR-T cell therapies rely on patient-derived cells, which can be costly and time-consuming to manufacture, hindering widespread adoption.
Solution
Genocury is developing off-the-shelf, iPSC-derived CAR-NKT cell therapies designed to be more affordable and accessible for cancer patients. The company leverages gene editing and directed differentiation technologies to create universal immune cell therapies. Their approach focuses on enhancing the specificity and efficacy of immune cells against tumors while reducing manufacturing costs and improving scalability. By utilizing iPSC-derived cells, Genocury aims to provide a readily available and cost-effective alternative to traditional autologous CAR-T cell therapies. The company's pipeline includes in vivo CAR-T and iPS-derived CAR-iNK cell therapies.
Target Audience
The primary target audience includes cancer patients seeking affordable and accessible cell therapies, as well as hospitals and oncology clinics looking to expand their treatment options with cost-effective solutions.
Features
- iPSC reprogramming and directed differentiation platform for generating immune cells
- Gene editing technologies to enhance CAR-NKT cell specificity and efficacy
- In vivo CAR-T technology that delivers CAR molecules to T cells within the patient's body
- Enhanced iNK cell platform for improved tumor cell killing
- Development of tissue-specific lentiviral vectors for targeted gene delivery
- Custom iPS cell line generation services
- Contract manufacturing of iPS-derived NK, CAR-NK, and CAR-T cells
- Development of customized disease-specific immune models